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Recent studies have demonstrated that one-third of known microRNAs (miRNAs) are stably detectable in plasma. Therefore, we
assessed plasma miRNAs to investigate the dynamics of oncomir 17-92a, which is highly expressed in multiple myeloma (MM)
patients. The plasma miR-92a level in symptomatic MM patients was signiﬁcantly downregulated compared with normal
subjects (Po0.0001), regardless of immunoglobulin subtypes or disease stage at diagnosis. In contrast, miR-92a levels in
peripheral blood CD8
þ or CD4
þ cells from MM patients were lower than those of normal subjects, and the miR-92a levels of
the cells tended to correlate with plasma miR-92a levels. The plasma miR-92a level in the complete remission group became
normalized, whereas the partial response (PR) and very good PR groups did not reach the normal range. In smoldering MM,
the plasma miR-92a level did not show a signiﬁcant difference compared with normal subjects. Our ﬁndings suggest that
measurement of the plasma miR-92a level in MM patients could be useful for initiation of chemotherapy and monitoring
disease status, and the level may represent, in part, the T-cell immunity status of these patients.
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INTRODUCTION
MicroRNAs (miRNAs) consist of approximately 18--22-nucleotide
non-coding RNA molecules that regulate posttranscriptional gene
expression by degradation or repression of mRNA molecules.
1- -3
Individual miRNAs can target multiple mRNAs and control
transcription in approximately one-third of human genes. Recent
studies have shown that these miRNAs are closely involved in
cell differentiation, proliferation, apoptosis or oncogenesis.
1- -3
In various human cancer, there is evidence of the alteration of
tumor tissue-speciﬁc miRNA.
4- -6 A 2008 study demonstrated that
miRNAs stably exist in serum and plasma,
7,8 and a recent advance
revealed the presence of circulating miRNAs within lipoprotein
(known as microvesicles), which may help to protect the miRNAs
from RNase-dependent degradation.
9,10 Moreover, some extracel-
lular circulating miRNAs in blood plasma are independent of
exosomes and are bound to Ago2 protein, resulting in strong
nuclease/proteinase resistance,
11 thus indicating a possible role of
circulating miRNAs in healthy subjects and disease condition.
7,8
The biological relevance of circulating miRNAs remains unclear,
although they may have an important role in cancer metastasis or
neo-angiogenesis. Therefore, circulating miRNAs are thought to
be possible diagnostic or prognostic biomarkers of human
diseases.
12- -14
It is well-known that multiple myeloma (MM) cells have a high
expression level of the miR-17-92a cluster,
15 whereas plasma
miR-92a levels in acute lymphoid leukemia or non-Hodgkin’s
lymphoma are extremely downregulated.
16- -18 Downregulation of
miRNAs, let-7a and miR-16 in myelodysplastic syndromes also has
been reported, and their levels were signiﬁcantly associated with
progression-free survival and overall survival, suggesting that
certain miRNAs in plasma can serve as noninvasive biomarker in
hematologic malignancies.
19 To gain more insight into the clinical
relevance of plasma miR-92a expression, we evaluated plasma
miR-92a levels in MM patients at various phases and in patients
with related disorders. In addition, we examined cellular miR-92a
levels in circulating lymphocytes obtained from untreated MM
patients and compared them with the plasma miR-92a level
to ascertain the possible association between immunological
condition and plasma miR-92a expression.
MATERIALS AND METHODS
Patients and samples
We evaluated peripheral blood obtained from 168 patients with
monoclonal gammopathies: 138 with symptomatic MM, 8 with smoldering
MM (SMM) and 22 with monoclonal gammopathy of undetermined
signiﬁcance (MGUS). The diagnosis of monoclonal gammopathy was
based on the deﬁnition of the International Myeloma Working Group using
the level of serum M-protein, proportion of plasma cells in bone marrow
and the presence of end-organ damage.
20 At the time of plasma collection,
the disease status of the 138 patients with symptomatic MM was as
follows (Table 1): 62 newly diagnosed, 8 complete remission (CR), 11 very
good partial response (VGPR), 15 partial response (PR), 14 stable
disease and 28 progressive disease. None of the 62 newly diagnosed
MM patients had del(13q) anomaly, where the miR-17-92a located,
according to the standard cytogenetic technique. Of the eight SMM
patients, two had received cytotoxic therapy because of an increase
in M-protein (X5g/dl). No MGUS patients had received chemotherapy
before plasma collection. We analyzed plasma from 113 normal individuals
and isolated lymphocytes from 21 healthy volunteers as the control.
These samples were handled similarly to those obtained from MM
patients.
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TaqMan low-density array screening
Total RNA was isolated with the mirVana PARIS kit (Ambion, Austin, TX,
USA). Plasma samples from ﬁve patients or ﬁve healthy individuals were
mixed evenly, and 500ml of mixed plasma was diluted with 500mlo f
binding solution. After a 5-min incubation, 1mlo f1 n M ath-miR-159
(Hokkaido System Science, Hokkaido, Japan) was added to each aliquot,
followed by vortexing for 30s and incubation on ice for 10min.
Subsequent phenol extraction and ﬁlter cartridge work was performed
according to the manufacturer’s instructions. In all, 3ml of RNA solution
from the 50-ml elute was used as an input in each reverse transcription (RT)
reaction. The RT reaction and pre-ampliﬁcation step were set up according
to the manufacturer’s recommendations. miRNAs were reverse transcribed
with the Megaplex Primer Pools (Human Pools A v2.1; Applied Biosystems,
Foster City, CA, USA). RT reaction products from the plasma sample were
further ampliﬁed with Megaplex PreAmp Primers (Primers A v2.1). The
expression proﬁle of the miRNAs was determined with the Human TaqMan
miRNA Arrays A (Applied Biosystems). Quantitative RT-PCR was performed
on an Applied Biosystems 7900HT thermocycler according to the
manufacturer’s recommended program. With the use of SDS2.2 software
and DataAssist (Applied Biosystems), the expression of plasma miRNAs was
calculated based on their Ct values normalized by those of ath-miR-159,
which was spiked in each plasma sample.
miR-92a quantitative RT-PCR
Total RNA in cells was isolated with an miRNeasy Mini Kit (Qiagen,
Germantown, MD, USA), and RNA in plasma was extracted as reported
previously.
17,18 miRNAs were quantiﬁed with TaqMan MicroRNA Assays
(Applied Biosystems) with modiﬁcation and miRNA-speciﬁc stem-loop
primers (has-miR-92a, 000431; has-miR-638, 001582; Applied Biosystems),
as we reported previously.
17,18 The plasma miR-92a expression was
normalized to miR-638 expression, and the cellular miR-92a expression
levels were normalized to RNU6B (001093; Applied Biosystems). We have
never detected U6B in a plasma sample, although U6B is commonly used
as an internal standard for miRNA expression analysis in cells. To normalize
the expression level of miR-92a in plasma, we compared plasma miR-92a
expression using an external standard, cel-miR-39 (Hokkaido System
Science), as well as an internal standard, miR-638, which is stably detected
in all samples. The results using miR-638 are compatible with those using
cel-miR-39 (data not shown). We therefore used miR-638 as a reference in
each plasma sample, as previously reported.
17,18
Lymphocyte separation
The CD4
þ or CD8
þ T-cell fractions were separated with an isolation kit for
humans (Miltenyi Biotec, Bergisch Gladbach, Germany) and AutoMACS Pro
Separator (Miltenyi Biotec), according to the supplier’s instruction, and
stored at  801C until use.
Statistical analysis
GraphPad 5.0 software (GraphPad Software Inc, San Diego, CA, USA) was
used for statistical analysis. The Mann- -Whitney test was used to determine
statistical signiﬁcance between two groups and one-way ANOVA for three
or more groups. We also used the Chi-square test and Student’s t-test,
when appropriate. P-values o0.05 were considered to indicate statistically
signiﬁcant differences.
RESULTS
Identiﬁcation of differentially expressed plasma miRNAs in
MM patients and healthy volunteers
Plasma miRNA expression was initially screened using the TaqMan
low-density array system. Of the 381 miRNAs represented on the
well plates, 331 miRNAs were not detected after the 35 PCR cycles.
Among the remaining 50 miRNAs, upregulated and down-
regulated miRNAs in MM plasma samples (expression level in
the sample was 4-fold greater or lower than that of healthy
volunteers) were selected. We then evaluated the rank order of
expression of each miRNA by DCt value among all detected
miRNAs.
Most of the miRNAs were downregulated in plasma samples
obtained from MM patients (Figure 1a). The most striking
difference of expression was found in miR-223. In addition,
members of the miR-17-92a cluster (miR-19b, miR-17, miR-92a,
miR-20a and miR-19a) were signiﬁcantly decreased in MM
Table 1. Plasma miR-92a/miR-638 expression levels in monoclonal gammopathies
Number of subjects Median Mean Standard error Minimum Maximam 95% CI
Normal 113 1.244 1.388 0.06993 0.2154 3.58 1.249- -1.527
Symptomatic MM at diagnosis 62 0.05202 0.1008 0.01899 0.000045 0.8586 0.06285- -0.1388
Myeloma subtype
Ig G 26 0.06107 0.121 0.03378 0.000045 0.8586 0.05146- -0.1906
Ig A 12 0.1508 0.05435 0.1901 0.006992 3.127 0.3020- -1.089
Ig D 3 0.1667 0.2353 0.1423 0.0304 0.5087  0.3769- -0.8475
Bence--Jones protein 14 0.03866 0.0973 0.04252 0.004289 0.6177 0.005448- -0.1892
Non-secretory myeloma 4 0.06367 0.07089 0.02974 0.01013 0.1461  0.02376- -0.1655
Plasma cell leukemia 3 0.02628 0.03341 0.01985 0.003151 0.07081  0.05201- -0.1188
Disease status of MM
Newly diagnosed 62 0.05202 0.1008 0.01899 0.000045 0.8586 0.06285- -0.1388
CR 8 1.494 1.602 0.354 0.2285 3.643 0.7653- -2.439
VGPR 11 0.2176 0.3591 0.09528 0.04138 1.028 0.1468- -0.5714
PR 15 0.8179 0.7967 0.2018 0.1216 1.979 0.5409- -1.052
Stable disease 14 0.3404 0.4251 0.2634 0.003508 0.9965 0.2479- -0.6022
Progressive disease 28 0.06335 0.2018 0.04978 0.003319 0.8586 0.09962- -0.3039
SMM 8 0.7943 1.188 0.4791 0.09087 5.242 0.3002- -1.348
MGUS 22 0.4055 0.6403 0.1309 0.007652 2.428 0.3681- -0.9124
Abbreviations: CI, conﬁdence interval; CR, complete remission; MGUS, monoclonal gammopathy of undermined signiﬁcance; MM, multiple myeloma;
PR, partial response; SMM, smoldering MM; VGPR, very good partial response. Disease status of multiple myeloma was categorized by International Myeloma
Workshop Consensus criteria.
20
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samples, the Ct values were generally low in both MM samples
and normal controls (Figure 1b). We therefore focused on
downregulation of the miR-17-92a cluster, rather than the single
miRNA (that is, miR-223), because the expression of miR-17-92a
cluster is essential in the lymphoid ontogeny and measured the
expression level of miR-92a in a large series of patients.
Plasma miR-92a level of symptomatic MM
Plasma miR-92a levels were signiﬁcantly lower in newly diagnosed
MM patients (n¼62) compared with healthy controls (Student’s
t-test: Po0.0001); the level of plasma miR-92a in symptomatic
MM patients was o10% compared with normal subjects
(mean±standard error 0.1008±0.01899 vs 1.388±0.06993;
Table 1). Among the MM patients, there were no signiﬁcant
differences in the plasma miR-92a levels, irrespective of MM
subtype (P¼0.4472) (Figure 2a), light chain type (P¼0.4413)
(Supplementary Figure 1A) or International Staging System
staging (P¼0.1955) (Supplementary Figure 1B). The presence of
anemia (P¼0.0990), bone lesion (P¼0.6701), renal damage
(P¼0.4258) or hypercalcemia (P¼0.1989) did not affect plasma
miR-92a level at MM diagnosis (Supplementary Figure 2AD,
Supplementary Table 1). Plasma miR-92a level was not correlated
with beta2 microglobulin elevation (P¼0.3675), albumin level
(P¼0.0693), elevated lactate dehydrogenase (P¼0.4863) or
performance status (P¼0.9850) (Supplementary Table 1).
The receiver operating characteristic curve was generated by
comparing the patients’ DCt values with those of healthy
volunteers. The analysis showed that miR-92a was a good marker
of newly diagnosed MM (AUC¼0.9810), indicating 91.94%
sensitivity (95% conﬁdence interval: 82.17--97.33%) and 99.12%
speciﬁcity (95% conﬁdence interval: 95.17--99.98%) when the cut-
off levels of plasma miR-92a in MM patients at diagnosis could be
achieved (that is, 0.2593) (Figure 2b).
Plasma miR-92a level in the various states of MM
We next compared the plasma miR-92a level in MM patients in
various clinical states (Table 1). Patients in CR (n¼8) had a
signiﬁcant increase in plasma miR-92a compared with those at
diagnosis (Po0.0001), and seven out of the eight patients were
normalized (X0.2593 cut-off level). Of the PR patients (n¼15), a
signiﬁcant increase in plasma miR-92a was notable (Po0.0001),
but these patients still had low plasma miR-92a compared with
normal subjects (P¼0.0033). Although patients with stable
disease (n¼14) had a partially normalized plasma miR-92a level,
three patients had an extremely low level, similar to those of
patients with newly diagnosed MM. In progressive disease
patients (n¼28), the plasma miR-92a level again downregulated
and no signiﬁcant difference was notable compared with newly
diagnosed MM (Figure 3a).
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Figure 2. Plasma miR-92a values in MM and receiver operating
characteristic curve. (a) Plasma miR-92a level (miR-92a/miR-638)
in patients with MM at the time of diagnosis. A signiﬁcant
downregulated plasma miR-92a level is notable in MM at diagnosis
(MM-Dx) (Po0.0001). No particular difference in plasma miR-92a
level is evident among immunoglobulin subtypes, Bence--Jones
protein type or non-secretory MM by one-way ANOVA. Bars indicate
minimum to maximum plasma miR-92a levels and boxes indicate
95% conﬁdence interval (CI). (b) The cut-off level of plasma miR-92a/
miR-638 in all MM at diagnosis is 0.2593. The sensitivity is 91.94%
(95% CI: 82.17--97.33%) and speciﬁcity is 99.12% (95% CI: 95.17--
99.98%).
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Figure 1. Identiﬁcation of expressed plasma miRNAs in MM.
(a) Downregulated miRNAs in MM (open bars). The expression
level in the sample was 4-fold lower than that of normal controls
(solid bars). Arrows indicate miR-17-92a polycistronic cluster. (b)
Upregulated miRNAs in MM (open bars). The expression level in the
sample was 4-fold higher than that of normal controls (solid bars).
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We also measured plasma miR-92a levels in 8 patients with SMM
and 22 with MGUS (Table 1). Compared with normal subjects,
patients with SMM showed no signiﬁcant differences in plasma
miR-92a levels (P¼0.4642), but they had elevated levels
compared with MM patients (P¼0.0496) (Figure 3b). The plasma
miR-92a level was signiﬁcantly decreased in MGUS patients
compared with normal subjects (Po0.0001), but they had
signiﬁcantly higher plasma miR-92a levels compared with MM
patients (P¼0.0005). No difference in plasma miR-92a levels was
noted between SMM and MGUS patients (P¼0.2959). The plasma
miR-92a levels did not correlate with duration between the time of
diagnosis of MGUS and the measurement of levels in this study
(data not shown).
miR-92a level in separated lymphocytes
We then compared miR-92a levels in T lymphocytes obtained from
healthy subjects (n¼21) with those of MM patients at diagnosis
(n¼6) or at CR/VGPR status (n¼5). The miR-92a level in CD4
þ or
CD8
þ T lymphocytes in MM patients at diagnosis was signiﬁcantly
lower compared with that of healthy subjects (CD4
þ: P¼0.0178;
CD8
þ: P¼0.0092) (Figure 4a). Comparison of miR-92a of CD4
þ and
CD8
þ T lymphocytes showed a roughly linear correlation, and most
MM patients in CR/VGPR status had an increased level (Figure 4b).
Although no apparent correlation was evident in normal subjects,
MM patients with low levels of plasma miR-92a had low levels of
miR-92a expression in CD4
þ (Figure 4c) and CD8
þ Tl y m p h o c y t e s
(Figure 4d), and three out of the ﬁve MM patients with CR/VGPR
had normal levels of plasma and cellular miR-92a.
DISCUSSION
The use of plasma miRNAs as potential biomarkers is a growing
research area,
12- -14 and this is the ﬁrst study to look at plasma
miRNAs in MM. Our ﬁndings indicate the possible clinical utility of
plasma miRNA level in MM patients. The recent introduction of
new agents has improved the response rate and survival in
patients with MM.
21 In MM treatment, the decision to start
chemotherapy usually depends on the presence of clinical
symptoms with high evidence level, so-called CRAB (hypercalce-
mia, renal failure, anemia, bone lesion) symptoms.
22 Moreover, the
therapeutic target point in MM patients has been proposed,
23 and
practical guidelines for the therapeutic strategy have been helpful
in clinical decision-making for MM treatment.
24,25 However, there
are some MM patients for whom the timing and combination of
chemotherapy are difﬁcult to decide,
26 although high-risk MM
patients can be classiﬁed.
27,28 Because, decisions regarding
chemotherapy are occasionally difﬁcult in non-secretory or
asymptomatic MM patients, a novel diagnostic marker is urgently
required, in addition to the conventional diagnostic tool.
21 In the
current study, we demonstrated the downregulation of plasma
miR-92a in symptomatic MM patients, irrespective of the presence
or absence of renal damage or M-protein, suggesting that the
measurement of the plasma miR-92a could be helpful for deciding
when to initiate chemotherapy.
Chromosomal abnormalities and molecular alterations in MM
cells have been extensively investigated, and some of them are
currently incorporated into the risk analysis.
23,27,29 In addition,
pathogenesis of extracellular circumstances, including angiogen-
esis,
30 in MM patients is an important issue not only for
understanding the biology of myeloma but therapeutic strategies
as well.
21 In myeloma cells, overexpression of the miR-17-92a has
been noted in the transformation from MGUS to MM.
15 Therefore,
miR-17-92a expression is thought to correlate with tumor burden in
MM patients. In contrast, we found no difference in plasma miR-92a
levels between MGUS and SMM patients. Because the plasma miR-
92a level was signiﬁcantly different between patients with SMM
and symptomatic myeloma, the level of plasma miR-92a level could
reﬂect the pathological condition of patients rather than the tumor
burden of myeloma cells in the body. Moreover, normalization of
the plasma miR-92a level after obtaining CR suggests that the
plasma miR-92a level might serve as an indicator for therapeutic
response. The number of treated patients studied was small,
however, and further research is needed to clarify this possibility.
Studies have shown that some circulating miRNAs in cancer-
bearing patients are tumor-derived,
7 and thus such miRNAs might
be used as biomarkers of cancer.
12- -14 The downregulation of
plasma miR-92a has been recognized in patients with hematologic
neoplasia, including acute leukemia,
16,17 non-Hodgkin’s lympho-
ma
18 and hepatocellular carcinoma,
31 as well as in patients with
cardiovascular diseases.
32 Because miR-17-92a is essential in
the development and ontogeny of the lymphoid system,
33,34
we examined the correlation between miR-92a levels in separated
lymphocytes and plasma. The plasma miR-92a levels was
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Figure 3. Plasma miR-92a expression in MM at various clinical phases
and SMM or MGUS. (a) The downregulated plasma miR-92a level at
myeloma diagnosis (MM-Dx) was normalized in CR (MM-CR) and was
partially normalized at VGPR (MM-VGPR) or PR (MM-PR) phase. (b)
Patients with SMM had a higher plasma miR-92a level than that of
symptomatic myeloma (P¼0.0496), but they had low levels
compared with normal subjects. Although some patients with MGUS
had low levels of plasma miR-92a, most MGUS patients had plasma
miR-92a levels similar to those with SMM. Bars indicate minimum to
maximum plasma miR-92a levels and boxes indicate 95% CI.
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CD8
þ lymphocytes. Some MM patients in CR/VGPR showed
normalization of the plasma miR-92a level, in combination with
upregulation of T-cell miR-92a. A recent study reported that the
miR-17-92a cluster was critical for optimal T-lymphocyte
co-stimulation via CD28 and was thereby essential for regulatory
T function under certain conditions.
35 Moreover, it is reported that
the type-1-skewing tumor microenvironment induces down-
regulation of miR-17-92a expression, with decreased levels of
miR-17-92a noted in both CD4
þ and CD8
þ cells in tumor-bearing
mice and in CD4
þ cells in patients with glioblastoma multi-
forme.
36 Together, these ﬁndings suggest that the low level of
miR-92a in T lymphocytes may represent dysregulation of
immunity and the downregulated plasma miR-92a level in MM
patients may reﬂect the dysfunction of T lymphocytes in vivo.I n
addition to miR-17-92a downregulation, the TaqMan low-density
array screening revealed downregulation of miR-223, a regulator
of neutrophil proliferation and activation.
37 The ultimate down-
regulation of plasma miR-223 in MM patients might also be
related with granulocyte dysfunction.
In conclusion, the plasma miR-92a level may serve as a
biomarker for monitoring therapeutic response in MM patients
and disease progression in asymptomatic MM patients. The
downregulated plasma miR-92a level may be linked to the
expression level of T-cell-derived miR-92a. Although we examined
a small number of patients, especially MM patients who had been
treated, these initial ﬁndings suggest that plasma miR-92a levels in
monoclonal gammopathy patients may be a promising parameter
not only for determining disease status but also whether further
treatment is required.
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Figure 4. Cellular miR-92a in CD8þ or CD4þ lymphocytes in MM and normal subjects. (a) The CD4þ miR-92a (P¼0.0178) and CD8þ
miR-92a (P¼0.0092) are signiﬁcantly downregulated. (b) Comparison between miR-92a levels in CD4
þ and CD8
þ T lymphocytes in normal
subjects (closed circles), MM at diagnosis (open squares) and myeloma in CR/VGPR (open triangles), showing a positive correlation.
Comparison between plasma miR-92a and the cellular miR-92a of CD4
þ T lymphocytes (c) or CD8
þ T lymphocytes (d) in identical subjects.
Myeloma patients with low levels of miR-92a in CD4
þ T lymphocytes cluster at low levels of plasma miR-92a, and some MM patients with
CR/VGPR show normalization of miR-92a levels in plasma, CD4
þ and CD8
þ T lymphocytes.
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